Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 6
2023 4

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean siri p[au] (16 results)?
Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis.
Karampitsakos T, Papaioannou O, Dimeas I, Tsiri P, Sotiropoulou V, Tomos I, Papanikolaou IC, Katsaras M, Kirgou P, Daniil Z, Gourgoulianis KI, Sampsonas F, Manali E, Papiris S, Bouros D, Tzouvelekis A. Karampitsakos T, et al. Among authors: tsiri p. ERJ Open Res. 2022 May 3;8(2):00082-2022. doi: 10.1183/23120541.00082-2022. eCollection 2022 Apr. ERJ Open Res. 2022. PMID: 35509438 Free PMC article.
Clinical outcomes in vaccinated and unvaccinated patients with COVID-19: a population-based analysis.
Papaioannou O, Karampitsakos T, Tsiri P, Sotiropoulou V, Koulousousa E, Tasiopoulos P, Schinas G, Katsaras M, Zarkadi E, Malakounidou E, Georgiopoulou V, Sampsonas F, Spyridonidis A, Akinosoglou K, Marangos M, Tzouvelekis A. Papaioannou O, et al. Among authors: tsiri p. Eur Rev Med Pharmacol Sci. 2022 Oct;26(20):7705-7712. doi: 10.26355/eurrev_202210_30047. Eur Rev Med Pharmacol Sci. 2022. PMID: 36314348 Free article.
Corrigendum: Post-COVID-19 interstitial lung disease: Insights from a machine learning radiographic model.
Karampitsakos T, Sotiropoulou V, Katsaras M, Tsiri P, Georgakopoulou VE, Papanikolaou IC, Bibaki E, Tomos I, Lambiri I, Papaioannou O, Zarkadi E, Antonakis E, Pandi A, Malakounidou E, Sampsonas F, Makrodimitri S, Chrysikos S, Hillas G, Dimakou K, Tzanakis N, Sipsas NV, Antoniou K, Tzouvelekis A. Karampitsakos T, et al. Among authors: tsiri p. Front Med (Lausanne). 2023 Apr 13;10:1194925. doi: 10.3389/fmed.2023.1194925. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37122328 Free PMC article.
Clinical features and outcomes of patients with myositis associated-interstitial lung disease.
Karampitsakos T, Tzilas V, Papaioannou O, Chrysikos S, Vasarmidi E, Juge PA, Vizirianaki S, Bibaki E, Reppa A, Sidiropoulos P, Katsaras M, Sotiropoulou V, Tsiri P, Koulousousa E, Theochari E, Tsirikos G, Christopoulos I, Malakounidou E, Zarkadi E, Sampsonas F, Hillas G, Karageorgas T, Daoussis D, Kalogeropoulou C, Dimakou K, Tzanakis N, Borie R, Dieudé P, Antoniou K, Crestani B, Bouros D, Tzouvelekis A. Karampitsakos T, et al. Among authors: tsiri p. Front Med (Lausanne). 2023 Jan 9;9:1096203. doi: 10.3389/fmed.2022.1096203. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36698813 Free PMC article.
Safety and Effectiveness of Mycophenolate Mofetil in Interstitial Lung Diseases: Insights from a Machine Learning Radiographic Model.
Karampitsakos T, Kalogeropoulou C, Tzilas V, Papaioannou O, Kazantzi A, Koukaki E, Katsaras M, Bouros E, Tsiri P, Tsirikos G, Zarkadi E, Ntoulias N, Sotiropoulou V, Efthymiou P, Chrysikos S, Malakounidou E, Sampsonas F, Bouros D, Tzouvelekis A. Karampitsakos T, et al. Among authors: tsiri p. Respiration. 2022;101(3):262-271. doi: 10.1159/000519215. Epub 2021 Sep 30. Respiration. 2022. PMID: 34592744
Post-COVID-19 interstitial lung disease: Insights from a machine learning radiographic model.
Karampitsakos T, Sotiropoulou V, Katsaras M, Tsiri P, Georgakopoulou VE, Papanikolaou IC, Bibaki E, Tomos I, Lambiri I, Papaioannou O, Zarkadi E, Antonakis E, Pandi A, Malakounidou E, Sampsonas F, Makrodimitri S, Chrysikos S, Hillas G, Dimakou K, Tzanakis N, Sipsas NV, Antoniou K, Tzouvelekis A. Karampitsakos T, et al. Among authors: tsiri p. Front Med (Lausanne). 2023 Jan 17;9:1083264. doi: 10.3389/fmed.2022.1083264. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36733935 Free PMC article.
Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study.
Karampitsakos T, Malakounidou E, Papaioannou O, Dimakopoulou V, Zarkadi E, Katsaras M, Tsiri P, Tsirikos G, Georgiopoulou V, Oikonomou I, Davoulos C, Velissaris D, Sampsonas F, Marangos M, Akinosoglou K, Tzouvelekis A. Karampitsakos T, et al. Among authors: tsiri p. Respir Res. 2021 Dec 22;22(1):317. doi: 10.1186/s12931-021-01914-6. Respir Res. 2021. PMID: 34937570 Free PMC article.
Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.
Karampitsakos T, Papaioannou O, Tsiri P, Katsaras M, Katsimpris A, Kalogeropoulos AP, Malakounidou E, Zarkadi E, Tsirikos G, Georgiopoulou V, Sotiropoulou V, Koulousousa E, Chourpiliadi C, Matsioulas A, Lagadinou M, Sampsonas F, Akinosoglou K, Marangos M, Tzouvelekis A. Karampitsakos T, et al. Among authors: tsiri p. Clin Microbiol Infect. 2023 Mar;29(3):372-378. doi: 10.1016/j.cmi.2022.10.015. Epub 2022 Oct 20. Clin Microbiol Infect. 2023. PMID: 36273769 Free PMC article.